Accera Inc. to Present at UBS Global Life Sciences Conference
September 18, 2009
Broomfield, CO, September 18, 2009 – Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system diseases, announced today that it will present at the UBS Global Life Sciences Conference September 21-23, 2009 in New York.
Steve Orndorff, Ph.D., founder, president and CEO, will provide a corporate overview of Accera and an update on Axona™ on Monday, September 21 at 11:30 a.m. EDT.
Axona is a first-in-class medical food for the clinical dietary management of the metabolic processes associated with mild-to-moderate Alzheimer's disease. Dispensed by prescription, Axona targets the metabolic deficiencies and imbalances associated with Alzheimer's disease by providing an alternative energy source for brain cells. With simple administration and once-a-day convenience, Axona is complementary to current Alzheimer's disease therapies. For more information about Axona, please visit www.about-axona.com or ask your physician.